BioProcess International is part of the Informa Connect Division of Informa PLC
Informa PLC
|
ABOUT US
|
INVESTOR RELATIONS
|
TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
About
Subscribe
Contribute
Subscribe
Subscribe
Upstream
Related Topics
Bioreactors
Expression Platforms
Biochemicals/Raw Materials
Cell Culture Media
Microbial Cell Culture
Perfusion Cell Culture
See all
Downstream
Related Topics
Filtration
Viral Clearance
Separation/Purification
Chromatography
See all
Manufacturing
Related Topics
Biosimilars
Continuous Bioprocessing
Facility Design/Engineering
Formulation
Single Use
Fill/Finish
Information Technology
Recent in
Manufacturing
See all
Monoclonal Antibody Productivity
Single Use
A Fully Single-Use Downstream Process for Monoclonal Antibodies
A Fully Single-Use Downstream Process for Monoclonal Antibodies
by
Shunsuke Shiina,
Neha Saxena
and 1 more
Apr 17, 2024
Artificial intelligence
Information Technology
Using Artificial Intelligence for Monoclonal Antibody Discovery
Using Artificial Intelligence for Monoclonal Antibody Discovery
by
William Whitford
Apr 17, 2024
Analytical
Related Topics
QA/QC
Cell Line Development
PAT
Product Characterization
Bioanalytical Methods
Process Development
Assays
See all
Business
Related Topics
Bioregions
Careers & Training
Contract Services
Economics
Pre-Clinical & Clinical Trials
Risk Management
Intellectual Property
Regulatory Affairs
See all
Therapeutic Modalities
Related Topics
Cell Therapies
Gene Therapies
MAb
Emerging Therapeutics
Personalized Medicine
Large Molecule Development
Vaccines
Recent in
Therapeutic Modalities
See all
Sino Biological’s Center for Bioprocessing (C4B) in Houston, TX
Emerging Therapeutics
Recombinant Antibody Technology: Its Criticality to Past and Future Biopharmaceutical Success
Recombinant Antibody Technology: Its Criticality to Past and Future Biopharmaceutical Success
by
Suranjana Sen
Apr 17, 2024
Characterization methodologies
Emerging Therapeutics
Intact and Subunit Molecular Mass Analysis for Development of Antibody Therapeutics: Considerations for Novel Biotherapeutics and Biosimilars
Intact and Subunit Molecular Mass Analysis for Development of Antibody Therapeutics: Considerations for Novel Biotherapeutics and Biosimilars
by
Sanjib Banerjee,
Rajiv Bharadwaj
Apr 17, 2024
BioProcess Insider
Related Topics
Deal-Making
Facilities & Capacity
Global Markets
Regulations
Therapeutic Class
Upstream & Downstream Processing
Webcasts
BioProcess Insider Podcasts
Recent in
BioProcess Insider
See all
thumbnail
Global Markets
From healthcare to health: 'No country can do this alone,' say experts in UAE
From healthcare to health: 'No country can do this alone,' say experts in UAE
by
Millie Nelson
May 14, 2024
2 Min Read
thumbnail
Global Markets
US looks to 2032 as cut-off from Chinese biomanufacturing reliance
US looks to 2032 as cut-off from Chinese biomanufacturing reliance
by
Dan Stanton
May 13, 2024
3 Min Read
Home
Vicky Qing Xia
Vicky Qing Xia
Latest from Vicky Qing Xia
Good Manufacturing Practice in China: Equipment Strategy and Quality Management to Compete with the West
Regulatory Affairs
Good Manufacturing Practice in China: Equipment Strategy and Quality Management to Compete with the West
Good Manufacturing Practice in China: Equipment Strategy and Quality Management to Compete with the West
by
Vicky Qing Xia
Jun 12, 2019
China Looks Inward and Outward: Investments in US and EU Biopharmaceutical Companies Are on the Rise
Bioregions
China Looks Inward and Outward: Investments in US and EU Biopharmaceutical Companies Are on the Rise
China Looks Inward and Outward: Investments in US and EU Biopharmaceutical Companies Are on the Rise
by
Vicky Qing Xia,
Eric S. Langer
May 17, 2019
All from Vicky Qing Xia
Bioregions
China Can Be Ignored No Longer: Long-Term Biopharmaceutical Opportunities Based on Near-Term Demonstrated Growth
China Can Be Ignored No Longer: Long-Term Biopharmaceutical Opportunities Based on Near-Term Demonstrated Growth
Mar 14, 2019
by
Vicky Qing Xia,
Eric S. Langer